Weight Management
Compounded GLP-1 Medications: What Patients Should Know
Compounded GLP-1 drugs were made while shortages allowed it; those shortages are now resolved. Here is what the FDA has said and what it means when you choose a program.
Reviewed by the clinical team at Zest Regen Health · September 23, 2026 · 7 min read
Content managed by Phil Kim, Lucky Consulting Group
Compounded GLP-1 medications are copies of FDA-approved prescription drugs such as semaglutide and tirzepatide, made by compounding pharmacies during the period those drugs were in shortage. In the United States, the FDA has declared both shortages resolved, and large-scale compounding of these products has wound down. If you are considering a GLP-1 weight loss program, understanding the difference between FDA-approved medication and compounded copies matters for safety, dosing, and quality.
What is a compounded medication?
Compounding is the practice of preparing a customized medication, usually because an approved version is unavailable, is in shortage, or cannot be tolerated by a specific patient. During the GLP-1 demand surge, compounding pharmacies began producing copies of semaglutide and tirzepatide under temporary allowances tied to the shortage. Those allowances were tied to shortage status, and that status has changed.
The shortages are now resolved in the United States
The FDA formally declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved on February 21, 2025. Transition periods allowed compounding to continue for a limited time, and those periods have passed. Large-scale compounding of semaglutide and tirzepatide copies is generally no longer permitted, and in April 2026 the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the bulk drug substances list used for bulk compounding, a step that would close the remaining industrial-scale pathway. As of October 2026, neither drug had returned to the shortage list and the proposal remained pending.
What the 2026 court rulings changed
The compounding industry challenged the shortage decisions in court, and those challenges failed. In August and September 2026, the U.S. Court of Appeals for the Fifth Circuit upheld the FDA determinations that the semaglutide and tirzepatide shortages were resolved, closing the remaining legal path for large-scale compounding tied to shortage status. With the April 2026 FDA proposal to remove semaglutide, tirzepatide, and liraglutide from the bulk drug substances list, industrial-scale compounding of these products no longer has a legal foundation. Patients who were taking compounded versions should discuss FDA-approved options with their clinician rather than continuing to source copies.
| Medication | Shortage status | What it means now |
|---|---|---|
| Semaglutide (Ozempic, Wegovy) | Declared resolved February 21, 2025 | Compounding of copies allowed only under limited, patient-specific circumstances |
| Tirzepatide (Mounjaro, Zepbound) | Declared resolved December 2024 | Same limited scope; transition periods have ended |
| Any GLP-1 bulk compounding | FDA proposal in April 2026 to remove them from the bulk list; Fifth Circuit upheld the rulings in 2026 | Industrial-scale compounding no longer has a legal pathway |
What the FDA has warned about compounded GLP-1s
- Compounded drugs are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality.
- A July 2024 FDA alert described dosing errors with compounded injectable semaglutide, some requiring hospitalization, driven mainly by confusion between milligrams, milliliters, and units when drawing from multi-dose vials.
- Some compounders use salt forms such as semaglutide sodium or semaglutide acetate, which are different active ingredients from the base semaglutide in approved products, with roughly 15% less active drug per milligram in the sodium form.
- Adverse event reports have risen: 605 for compounded semaglutide and 545 for compounded tirzepatide as of July 31, 2025, plus sterility and contamination-related recalls of some compounded products.
What this means when you choose a program
A program built around compounded GLP-1 copies may not be operating within current rules, and the product you receive may not have been reviewed for quality or accurate dosing. A physician-led weight loss program evaluates your health history first, works with appropriate medication options, and monitors your response over time. That is the difference between buying a vial and being treated as a patient.
How GLP-1 care works at Zest Regen Health
GLP-1 support at Zest Regen Health is part of a supervised medical weight loss program in Columbia, Maryland. Candidacy starts with an evaluation, testing comes before treatment, and dosing and follow-up are managed by the clinical team. Care is self-pay, and the team explains what is appropriate for your situation, what is not, and why.
Meet our physicians, who evaluate patients at Zest Regen Health (/dr-francisco-ward/).
Sources & further reading
- FDA: Dosing errors associated with compounded injectable semaglutide
- FDA: Declaratory order resolving the semaglutide injection shortage
- GoodRx: Are compounded GLP-1s going away?
- FDA: Policies for compounders as the national GLP-1 supply stabilizes
- Fifth Circuit upholds FDA GLP-1 shortage decisions, narrowing path for mass-market compounding (Clark Hill)
Next step
If you want to explore GLP-1 weight loss with a medically supervised program, book a free 15-minute consultation at the Columbia clinic. The team will review your history, explain what is currently available and appropriate, and outline exactly what a program would include.
Talk with our care team about this topic
A member of our clinical team can answer your questions at the Columbia, Maryland clinic. If GLP-1 Weight Loss Programs may be appropriate for you, the first step is a consultation.
Care at Zest Regen Health is physician-guided. Meet our physicians, who evaluate patients at the Columbia, Maryland clinic.